Posts Tagged ‘clopidogrel’

April 2nd, 2013

Selections from Richard Lehman’s Literature Review: April 2nd

This week’s topics include the TACT study of chelation therapy, off-pump vs. on-pump CABG, clopidogrel with or without aspirin in those taking oral anticoagulants and undergoing PCI, and more.

March 10th, 2013

ACC.13: Is Cangrelor an Antiplatelet CHAMPION?

, and

Deepak Bhatt sheds light on findings from the CHAMPION PHOENIX trial and their implications for clinical practice.

March 10th, 2013

Cangrelor During PCI May Reduce Ischemic Events

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters. In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet […]

January 8th, 2013

Early Results: Antiplatelet Drug Cangrelor Superior to Clopidogrel in PCI Patients at 48 Hours

The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The […]

November 4th, 2012

Platelet-Function Testing in Coronary Stenting: Frozen in Its Tracks

An ARCTIC trial investigator discusses possible reasons why antiplatelet-drug and dosing adjustments, guided by platelet-function testing, did not improve clinical outcomes for stented patients.

November 4th, 2012

ARCTIC Blows a Cold Wind on Platelet Function Tests

The use of platelet-function tests to monitor and guide antiplatelet therapy in PCI patients has sparked heated debate. Cardiologists have sought to reconcile biological plausibility with the absence of clinical evidence. Now the ARCTIC (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy versus a Monitoring-guided Strategy for Drug-Eluting Stent Implantation versus Continuation One […]

October 8th, 2012

Selections from Richard Lehman’s Literature Review: October 8th

This week’s topics include beta-blockers and the lack of a cardioprotective effect for certain patients; intra-aortic balloon support for MI with cardiogenic shock; prasugrel vs. clopidogrel for acute coronary syndromes without revascularization; CRP, fibrinogen, and CVD prediction; and a comparison of thrombectomy devices for acute ischemic stroke.

October 8th, 2012

Triple Antithrombotic Therapy: What — and When — Is the Bleeding Risk?


Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan’s questions about the study and its implications.

September 6th, 2012

Selections from Richard Lehman’s Literature Review: September 6th

This week’s topics includes studies on aspirin plus clopidogrel in patients with recent lacunar stroke and the risk of coronary events in patients with either CKD or diabetes.

September 4th, 2012

Danish Survey Finds Clopidogrel Less Effective in Diabetics

A large nationwide survey of MI survivors in Denmark provides new information about the efficacy of antiplatelet therapy with clopdiogrel in patients with diabetes. In a paper published in JAMA, Charlotte Andersson reports on 58,851 MI patients, 12% of whom had diabetes and 60% of whom received clopidogrel. As expected, diabetics had a worse outcome than nondiabetics: the composite […]